Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

Irinotecan Plus Mitomycin C as Second-Line Chemotherapy for Advanced Gastric Cancer Resistant to Fluoropyrimidine and Cisplatin: A Retrospective Study

Background. S-1 plus cisplatin has been established to be standard first-line chemotherapy for advanced gastric cancer in Japan. The optimal second-line treatment refractory to S-1 plus cisplatin remains unclear. Methods. We retrospectively studied the efficacy, toxicity, and survival of irinotecan...

Full description

Bibliographic Details
Main Authors: Kohei Ogawa, Ayumu Hosokawa, Akira Ueda, Seiko Saito, Hiroshi Mihara, Takayuki Ando, Shinya Kajiura, Mitsuhiro Terada, Yuji Tsukioka, Naoki Horikawa, Takashi Kobayashi, Masayuki Note, Kunihiro Sawasaki, Junya Fukuoka, Toshiro Sugiyama
Format: Article
Language:English
Published: Hindawi Limited 2012-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2012/640401

Internet

http://dx.doi.org/10.1155/2012/640401

Similar Items